The First FDA-approved Psilocin Clinical Trial

“Four Healthy subjects have been dosed with Filament’s botanical psilocybin and psilocin drug candidates.”

Filament is a clinical stage natural psychedelic drug development company out of Vancouver, currently in partnership with University of California San Francisco’s Translational Psychedelic Research Program. The study found all fifteen doses of Filament’s drug candidates to be well tolerated with no unexpected adverse events. This is the first FDA-approved clinical trial of a naturally-derived psychedelic drug, as well as the first time psilocin has been directly administered in a clinical trial. Surely, exciting data will to surface as this study continues as planned.